ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways.
ProJenX has raised $1.0M in total funding. The most recent round was Grant. The last funding was announced in June 2024.
ProJenX's investors include Medical Excellence Capital, The ALS Association.
ProJenX is headquartered in New Suffolk, United States.
ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways.
ProJenX is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ProJenX — Funding & Investors." VCBacked, June 20, 2024, https://www.vcbacked.co/company/projenx. Accessed September 30, 2026.
VCBacked. (2024). ProJenX — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/projenx
{{cite web |title=ProJenX — Funding & Investors |url=https://www.vcbacked.co/company/projenx |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated